Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. REGENXBIO Inc.
  6. News
  7. Summary
    RGNX   US75901B1070

REGENXBIO INC.

(RGNX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

REGENXBIO : RBC Lifts Price Target on REGENXBIO to $55 From $50, Sees Eye Care Deal With AbbVie as Positive; Sector Perform, Speculative Risk Kept

09/14/2021 | 09:36am EDT


ę MT Newswires 2021
All news about REGENXBIO INC.
10/12REGENXBIO : Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American So..
PU
10/12REGENXBIO INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits..
AQ
10/09REGENXBIO Inc. Presents Positive Initial Data from Phase II ALTITUDEÖ Trial of RGX-314 ..
CI
10/04REGENXBIO : Shares Tumble 20% Following Phase 2 RGX-314 Data
MT
10/01REGENXBIO : Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update a..
PU
10/01REGENXBIO INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits..
AQ
10/01REGENXBIO Inc. Announces Initial Data from the Ongoing Phase II AAVIATE Trial of RGX-31..
CI
09/27REGENXBIO Inc. Announces RGX-314 Data Presentations at Retina Society 54th Annual Scien..
CI
09/15INSIDER SELL : Regenxbio
MT
09/15WALL STREET STOCK EXCHANGE : Yes, the global economic recovery is slowing
More news
Analyst Recommendations on REGENXBIO INC.
More recommendations
Financials (USD)
Sales 2021 265 M - -
Net income 2021 -1,95 M - -
Net cash 2021 598 M - -
P/E ratio 2021 -40,7x
Yield 2021 -
Capitalization 1 547 M 1 547 M -
EV / Sales 2021 3,58x
EV / Sales 2022 7,85x
Nbr of Employees 306
Free-Float 87,3%
Chart REGENXBIO INC.
Duration : Period :
REGENXBIO Inc. Technical Analysis Chart | RGNX | US75901B1070 | MarketScreener
Technical analysis trends REGENXBIO INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 36,31 $
Average target price 65,13 $
Spread / Average Target 79,4%
EPS Revisions
Managers and Directors
Kenneth T. Mills President, Chief Executive Officer & Director
Vit Vasista Chief Financial Officer & Senior Vice President
Allan M. Fox Chairman
Curran M. Simpson SVP, Chief Operations & Technology Officer
Olivier Danos Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
REGENXBIO INC.-19.95%1 547
GILEAD SCIENCES, INC.16.98%85 447
WUXI APPTEC CO., LTD.29.45%65 650
BIONTECH SE207.08%60 460
REGENERON PHARMACEUTICALS15.01%57 767
VERTEX PHARMACEUTICALS-23.03%47 190